Heart Failure Treatment Denied by Insurance? Here's How to Fight Back

Heart failure affects nearly 6.7 million Americans, and the stakes of treatment decisions are literally life or death. Yet insurance companies routinely deny coverage for LVAD implants, cardiac resynchronization therapy (CRT), sacubitril/valsartan (Entresto), and remote hemodynamic monitoring. If your insurer has denied a heart failure treatment, this guide explains why denials happen and how to mount a winning appeal.

Why Insurers Deny Heart Failure Treatments

Insurance companies have financial incentives to delay or deny expensive heart failure interventions. Common denial reasons include:

"Not medically necessary" — The insurer's medical reviewer disagrees with your cardiologist's judgment. This is especially common with CRT-D devices when the insurer claims your ejection fraction doesn't meet their internal threshold, even when ACC/AHA guidelines support treatment.

"Step therapy not completed" — Your plan may require failure of cheaper medications before approving advanced therapies. Some insurers demand documented trials of ACE inhibitors, beta-blockers, and aldosterone antagonists before approving Entresto, even when current guidelines recommend starting Entresto earlier.

"Experimental or investigational" — Remote monitoring via devices like CardioMEMS may be labeled investigational despite strong clinical evidence and FDA approval. This argument crumbles quickly with published trial data.

LVAD-specific denials — Left ventricular assist device denials often cite lack of transplant eligibility documentation, failure to exhaust medical management, or questions about whether the device is "destination therapy" versus bridge to transplant.

Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization failures — Missing documentation, incomplete physician notes, or formulary restrictions on Entresto can trigger automatic denials before a human reviewer ever sees your case.

Key Clinical Frameworks That Support Your Appeal

When building your appeal, anchor it in established clinical guidelines:

ACC/AHA Heart Failure Guidelines — The 2022 ACC/AHA/HFSA Heart Failure Guideline gives Class I recommendations (highest level of evidence) for sacubitril/valsartan in patients with HFrEF who can tolerate ACE inhibitor/ARB therapy. If your insurer denies Entresto while citing step therapy, cite these guidelines directly.

CRT Criteria — ACC/AHA guidelines support CRT-D for patients with LVEF ≤35%, LBBB morphology, and QRS ≥150ms with NYHA Class II-IV symptoms on optimal medical therapy. Document your EKG findings and current medication regimen in your appeal.

LVAD Guidelines — INTERMACS criteria and the MOMENTUM 3 trial support LVAD therapy for patients with Stage D HFrEF. If denied for LVAD, submit your INTERMACS profile documentation and note that LVAD has Class IIa recommendation for non-transplant-eligible patients.

CardioMEMS Remote Monitoring — The CHAMPION trial demonstrated a 37% reduction in heart failure hospitalizations with CardioMEMS hemodynamic monitoring. The device has FDA approval and CMS coverage for NYHA Class III patients with a prior heart failure hospitalization. If denied as "experimental," cite CHAMPION trial data and CMS NCD language directly.

Step-by-Step Appeal Strategy

Step 1: Get the denial letter and EOB. Read every word. The denial must specify the exact clinical criteria used and the policy language invoked. Note whether this is a coverage denial, a medical necessity denial, or a prior authorization denial — each requires a different appeal approach.

Step 2: Obtain a detailed Letter of Medical Necessity. Your cardiologist should write a letter that directly addresses the insurer's stated reason for denial. It should cite your NYHA functional class, ejection fraction, current medications, symptom burden, and relevant clinical trial data. A form letter will not win an appeal — specificity matters.

Step 3: Gather supporting records. Include echocardiogram reports, BNP/NT-proBNP lab results, recent hospitalization records, and any prior failed medication trials. For CRT, include EKG with QRS measurements.

Step 4: File the internal appeal within deadline. ACA-regulated plans give you at least 180 days to file an internal appeal. Urgent/expedited appeals for life-threatening conditions must be decided within 72 hours. Use the expedited pathway if your condition is deteriorating rapidly.

Step 5: Request an Independent Medical Review (IMR). If the internal appeal is denied, you have the right under federal law to an External Independent Review: Complete Guide" class="auto-link">external review by an independent organization. External reviews overturn insurer denials at meaningful rates — roughly 40% for some categories of treatment.

Step 6: File a state insurance complaint. Your state insurance commissioner can investigate improper denials and force compliance. Many states have enacted gold-carding laws or step therapy reform laws that may apply to your situation.

Special Considerations for Heart Failure Appeals

Entresto step therapy reform — As of 2022, the Step Therapy for Heart Failure Act of 2022 (passed as part of the Consolidated Appropriations Act) requires group health plans to allow step therapy overrides when the standard therapy is contraindicated. Know your rights under this law.

Urgent care exceptions — If you have been hospitalized twice in the past year for heart failure decompensation, cite that history explicitly. Insurers must consider urgency and risk of deterioration in their review.

Medicare-specific rules — Medicare Advantage plans must follow CMS coverage determinations. If you have Medicare, file an expedited appeal through the Medicare appeals process and consider requesting a Qualified Independent Contractor (QIC) review.

Fight Back With ClaimBack

Heart failure is serious. You should not be fighting your insurance company alone while managing a life-threatening condition. ClaimBack helps you build a complete, evidence-based appeal using your medical records and the clinical guidelines that support your case.

Start your heart failure appeal at ClaimBack

Our platform guides you through documenting your NYHA class, gathering echo reports, and citing the ACC/AHA guidelines that directly counter your insurer's denial language.

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeals